Collegium Pharmaceutical, Inc. (354.F)
- Previous Close
25.80 - Open
25.20 - Bid 25.20 x 70000
- Ask 25.80 x 70000
- Day's Range
25.00 - 25.20 - 52 Week Range
22.00 - 38.60 - Volume
279 - Avg. Volume
4 - Market Cap (intraday)
822.3M - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
23.15 - EPS (TTM)
1.08 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
www.collegiumpharma.com357
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 354.F
View MorePerformance Overview: 354.F
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 354.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 354.F
View MoreValuation Measures
Market Cap
822.30M
Enterprise Value
1.40B
Trailing P/E
23.12
Forward P/E
4.12
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
3.87
Enterprise Value/Revenue
2.37
Enterprise Value/EBITDA
4.73
Financial Highlights
Profitability and Income Statement
Profit Margin
6.61%
Return on Assets (ttm)
7.95%
Return on Equity (ttm)
19.23%
Revenue (ttm)
664.28M
Net Income Avi to Common (ttm)
43.89M
Diluted EPS (ttm)
1.08
Balance Sheet and Cash Flow
Total Cash (mrq)
197.77M
Total Debt/Equity (mrq)
411.94%
Levered Free Cash Flow (ttm)
341.32M